Credit Suisse analyst Evan Seigerman reiterated an Outperform rating and $338.00 price target on Biogen (NASDAQ: BIIB) noting that the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE